7-hydroxy-butylphthalide nano-emulsion formulation, preparation method therefor and use thereof

By forming a complex with oil and phospholipids in 7-hydroxy-butylphthaline nano-milk preparations, the problem of its low solubility is solved, efficient loading and long cycles are achieved, and the stability and bioavailability in the body are significantly improved. , provides a new drug for stroke treatment.

WO2024250546A1PCT designated stage expired Publication Date: 2024-12-12NCPC NEW DRUG RES & DEV +1

Patent Information

Application Number
PCT/CN2023/129657
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-06-08
Filing Date
2023-11-03
Publication Date
2024-12-12

AI Technical Summary

Technical Problem

The water solubility of 7-hydroxy-butylphthalide is low, making it difficult for its patent medicine to meet the clinical drug needs, especially in the treatment of stroke, which is difficult to effectively deliver to the target site.

Method used

In the form of nano-milk preparations, 7-hydroxy-butylphthaline nano-milk preparations are prepared by forming complexes with molecules such as oil and phospholipids, and ultrasonic dispersion or rotary evaporation to improve their solubility and drug loading, and optimize phospholipids and phospholipids. The proportion and species of PEG derivatives to improve encapsulation rate and stability.

Benefits of technology

The efficient loading and long cycle of 7-hydroxy-butylphthalide has been achieved, which significantly improves its stability and bioavailability in vivo, has good histocompatibility and targeting effects, and has potential clinical treatment of tumors and Application value of stroke.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PCTCN2023129657-FTAPPB-I100001
    Figure PCTCN2023129657-FTAPPB-I100001
  • Figure PCTCN2023129657-FTAPPB-I100002
    Figure PCTCN2023129657-FTAPPB-I100002
  • Figure PCTCN2023129657-FTAPPB-I100003
    Figure PCTCN2023129657-FTAPPB-I100003
Patent Text Reader

Abstract

Provided are a 7-hydroxy-butylphthalide nano-emulsion formulation, a preparation method therefor and a use thereof. Specifically, a 7-hydroxy-butylphthalide nano-emulsion formulation containing a phospholipid PEG derivative is developed, and a molecular action mechanism of 7-hydroxy-butylphthalide, a phospholipid and a phospholipid PEG derivative in the formulation is disclosed by means of multi-scale calculation simulation; the specification of the formulation is determined by means of prescription and process optimization; and the effectiveness of the formulation in treating cerebral apoplexy is verified by means of animal in-vivo pharmacodynamics evaluation, providing a reliable dosage form for meeting clinical medication. The present invention solves the problems of poor solubility of 7-hydroxy-butylphthalide and difficulty in drug preparation. Upon quality inspection, the encapsulation efficiency, the particle size, the Zeta potential and the like of the 7-hydroxy-butylphthalide nano-emulsion formulation meet the quality requirements of nano-drug formulations, the 7-hydroxy-butylphthalide nano-emulsion formulation is applied to the treatment of cerebral apoplexy of rats, and the treatment effect shows that the 7-hydroxy-butylphthalide nano-emulsion formulation has the potential of clinically treating tumors and great application value.
Need to check novelty before this filing date? Find Prior Art

Description

7-Hydroxy-butylphthalide nanoemulsion preparation, preparation method and application thereof Technical Field

[0001] The present invention relates to the technical field of novel drug delivery systems in pharmacy, in particular to a 7-hydroxy-butylphthalide nanoemulsion preparation, a preparation method and application thereof. Background Art

[0002] Stroke, a highly prevalent cardiovascular disease, has become one of the diseases with the highest disability and mortality rates in my country. It not only causes extreme physical and psychological pain to patients, but also places a heavy burden on families and society. In previous research, the applicant discovered that 7-hydroxybutylphthalide has superior antiplatelet and antioxidant properties, offers enhanced protection against brain tissue damage caused by middle cerebral artery occlusion, and can effectively alleviate the sequelae of brain damage, making it a promising treatment for stroke. The applicant has applied for two invention patents: "A strain of Penicillium foetidum and a method for preparing L-7-hydroxybutylphthalide using the same" (ZL201510113631.9) and "Use of 7-hydroxybutylphthalide in the preparation of a drug for the prevention and / or treatment of cardiovascular and cerebrovascular diseases" (ZL201610538809.9). However, 7-hydroxybutylphthalide has low water solubility, which presents difficulties in its development as a drug. Therefore, how to use modern pharmaceutical technology to improve the solubility of 7-hydroxy-butylphthalide and make it into an injection to meet clinical medication needs is an important issue that needs to be solved urgently.

[0003] Strategies for improving the solubility of poorly soluble drugs primarily include latent dissolution, solubilization, and solubilization-assisted dissolution, as well as the use of novel drug delivery systems such as liposomes, nanoparticles, and nanoemulsions to create high-end, complex formulations. Nanoemulsion injections, due to their high drug loading capacity, excellent biocompatibility and bioavailability, as well as their simple preparation process, controlled quality, and ease of large-scale production, have become the preferred dosage form for addressing the drugability challenges of poorly soluble drugs. Currently, over ten drug-loaded nanoemulsion formulations have been approved for marketing, representing a significant share of the high-end, complex injectable market and a mature new dosage form.

[0004] Drug-loaded nanoemulsions are high-end, complex oil-in-water (O / W) formulations, made by dissolving the drug in oil and fat, emulsifying it with surfactants such as phospholipids, and dispersing it in an aqueous phase. Their particle size typically ranges from 100nm to 600nm. Nanoemulsions primarily consist of an oil phase, an emulsifier, and an aqueous phase. During high-pressure homogenization, the oil phase is evenly distributed in the aqueous phase in the form of lipid droplets, each of which is encapsulated by emulsifiers such as phospholipids. Phospholipids, acting as emulsifiers, embed their nonionic, hydrophobic tails within the lipid droplets, while their anionic, hydrophilic heads extend into the external aqueous phase, forming a tightly packed molecular membrane around the lipid droplets. This reduces the interfacial tension between the oil and water phases and improves the stability of the nanoemulsion. In nanoemulsions, poorly soluble drugs have good compatibility with oil and fat, and are therefore primarily loaded into the lipid droplets. Due to differences in drug molecular structure and interactions with oils and emulsifiers, drug loading in drug-loaded nanoemulsions varies significantly. For example, the loading of clevidipine in a nanoemulsion is 0.25% (w / w), while that of propofol is 10% (w / w). Therefore, only by deeply analyzing the interactions between 7-hydroxy-butylphthalide and other molecules such as oils and phospholipids, and optimizing the types of oils and phospholipids, can a 7-hydroxy-butylphthalide nanoemulsion formulation with high drug loading and good stability be achieved.

[0005] Summary of the Invention

[0006] The present invention aims to provide a 7-hydroxy-butylphthalide nanoemulsion preparation, a preparation method and application thereof, so as to improve the solubility of 7-hydroxy-butylphthalide, solve its drug formulation problem, and apply it to the treatment of stroke.

[0007] The present invention is achieved by providing a 7-hydroxy-butylphthalide nanoemulsion formulation comprising 7-hydroxy-butylphthalide, oil, phospholipid, phospholipid PEG derivative, surfactant, and isotonic agent. The nanoemulsion formulation is an oil-in-water nanoemulsion obtained by dispersing oil in an aqueous phase and emulsifying it with a surfactant such as a phospholipid. The phospholipid and 7-hydroxy-butylphthalide form a complex dispersed in the oil phase, and the phospholipid and phospholipid PEG derivative are distributed in the interface layer.

[0008] In the above scheme, the oil is selected from injectable soybean oil (LCT), medium-chain triglycerides (MCT), castor oil, olive oil, and sesame oil; LCT, MCT, and castor oil are preferred; and the oil concentration is preferably 5% to 30%. The phospholipid is selected from natural phospholipids such as egg yolk phosphatidylglycerol (EPG) and egg yolk phosphatidylcholine (PC-98T), and synthetic phospholipids such as dipalmitoylphosphatidylcholine (DSPC), dipalmitoylphosphatidylcholine (DPPC), and hydrogenated distearoylphosphatidylcholine (HSPC); PC-98T is preferred. The phospholipid PEG derivative is preferably distearoylphosphatidylethanolamine-polyethylene glycol (DSPE-PEG). The concentration of the phospholipid PEG derivative is 0.025 to 0.25%. The surfactant is selected from poloxamer F68 and oleic acid; and the isotonicity agent is glycerol.

[0009] In the above scheme, the complex formed by phospholipid and 7-hydroxy-butylphthalide is formed by hydrogen bonding and van der Waals forces between two 7-hydroxy-butylphthalide molecules and one phosphatidylcholine molecule; the synthesis process is ultrasonic dispersion or rotary evaporation; the phospholipids are hydrogenated distearoylphosphatidylcholine (HSPC) and egg yolk lecithin (PC-98T), preferably egg yolk lecithin (PC-98T).

[0010] A method for preparing a 7-hydroxy-butylphthalide nanoemulsion preparation comprises the following steps:

[0011] a. Dissolving phospholipids and 7-hydroxy-butylphthalide in ethanol, respectively, followed by ultrasonic mixing or rotary evaporation to remove the ethanol to obtain an oily liquid, and then adding oil, oleic acid, and a phospholipid PEG derivative to the oily liquid to obtain a clear oil phase;

[0012] b. Add surfactant and isotonic agent to water for injection in sequence, and dissolve by ultrasonic until clear to obtain aqueous phase;

[0013] c. Rapidly add the water phase to the oil phase under stirring with a high-speed shearing machine, and shear at high speed until the solution becomes uniform milky white to obtain colostrum;

[0014] d. The colostrum was transferred to a high-pressure homogenizer, homogenized, and then fixed to volume with water for injection to obtain a 7-hydroxy-butylphthalide nanoemulsion preparation.

[0015] In step a, the oils are soybean oil and medium-chain triglycerides in a ratio of 1:1 to 1:4 (by mass), with a total oil concentration of 5% to 30%. The phospholipid PEG derivative is present in a ratio of 1:100 to 20:100 (by mass), and the ratio of 7-hydroxybutylphthalide to the total oil is 1:100 to 5:100.

[0016] In the final preparation, the concentration of 7-hydroxy-butylphthalide is 0.25 mg / mL to 5.0 mg / mL, preferably 1.0 mg / mL.

[0017] The 7-hydroxy-butylphthalide nanoemulsion preparation prepared according to the method of the invention has an encapsulation rate of more than 80% and a particle size of 100-400 nm.

[0018] The 7-hydroxy-butylphthalide nanoemulsion prepared by the above method is administered by injection in the form of an injection solution or a powder injection, and is administered by intravenous push or intravenous drip. It has good tissue compatibility, is non-hemolytic, and does not damage normal tissues and organs.

[0019] The 7-hydroxy-butylphthalide nanoemulsion preparation provided by the present invention can be used for the treatment of cerebral stroke.

[0020] The invention provides a 7-hydroxy-butylphthalide nanoemulsion preparation (abbreviated as N3-LNE), which has high 7-hydroxy-butylphthalide loading capacity, long in vivo circulation and targeting effect. The present invention first uses multi-scale computational simulation to study the molecular interactions between the various components in N3-LNE, and proposes that the formation of a complex between 7-hydroxybutylphthalide and phospholipids is the key to improving its solubility and drug loading, which provides a theoretical basis and guidance for the construction of the preparation; by examining the solubility of 7-hydroxybutylphthalide in injectable oils and fats, the type of oil is optimized, and the differential scanning calorimetry technology is used to optimize the type of phospholipids that can form a stable complex with 7-hydroxybutylphthalide; the interfacial tension measurement technology is used to further optimize the type of phospholipids used as emulsifiers in the N3-LNE preparation; on this basis, a creative preparation process and prescription of N3-LNE are proposed: first, phospholipids and 7-hydroxybutylphthalide (N3) are dissolved in an appropriate amount of ethanol, ultrasonically mixed or rotary evaporated to remove the ethanol to obtain an oily liquid, and then oils and phospholipid PEG derivatives are added thereto to obtain a clear oil phase; after adding a surfactant and an isotonic agent to water for injection in sequence, ultrasonically dissolving the solution, The method comprises the following steps: stirring the colostrum and the oil phase, stirring the colostrum to clarify to obtain an aqueous phase; rapidly adding the aqueous phase to the oil phase under stirring in a high-speed shearing machine, and shearing at high speed until the solution becomes uniform milky white to obtain colostrum; transferring the colostrum to a high-pressure homogenizer, homogenizing, and adjusting the volume with water for injection to obtain a 7-hydroxy-butylphthalide nanoemulsion preparation; wherein the oil is selected from injectable soybean oil (LCT), medium-chain triglycerides (MCT), castor oil, olive oil, sesame oil, preferably LCT, MCT and castor oil; the phospholipid is selected from natural phospholipids such as egg yolk phosphatidylglycerol (EPG), egg yolk lecithin (PC-98T) and synthetic phospholipids such as dioleoylphosphatidylcholine (DOPC), dipalmitoylphosphatidylcholine (DPPC), hydrogenated distearoylphosphatidylcholine (HSPC), preferably PC-98T; the phospholipid PEG derivative is preferably distearoylphosphatidylethanolamine-polyethylene glycol (DSPE-PEG); the surfactant is selected from poloxamer (F68) and oleic acid; and the isotonic agent is glycerol.

[0021] The above-mentioned technical means have overcome the poor solubility and drug-making difficulties of 7-hydroxy-butylphthalide. Quality inspections have shown that its encapsulation efficiency, particle size, and zeta potential meet the quality requirements for nanopharmaceutical preparations. Its application in the treatment of stroke in rats has shown therapeutic efficacy, demonstrating that 7-hydroxy-butylphthalide nanoemulsion injection has potential for clinical tumor treatment and has great application value.

[0022] Compared with the prior art, the present invention is innovative in that:

[0023] (1) A novel 7-hydroxy-butylphthalide nanoemulsion injection formulation was prepared for the treatment of stroke, which has not been reported by others.

[0024] (2) The molecular interaction between the drug and the carrier in the preparation is explained: the present invention proposes for the first time that 7-hydroxy-butylphthalide forms a complex with phospholipids through hydrogen bonds and van der Waals forces, which is a key technology for improving the efficient encapsulation of 7-hydroxy-butylphthalide in nanoemulsions and provides a theoretical basis for the new preparation proposed by the present invention, which has not been reported by others; similar interactions also exist between 7-hydroxy-butylphthalide and phospholipid PEG derivatives, and the effective prescription amount of phospholipid PEG derivatives is 0.025-0.25%. Within this dosage range, the nanoemulsion preparation proposed by the present invention has a long circulation effect without reducing the drug encapsulation efficiency.

[0025] (3) A creative preparation process for 7-hydroxy-butylphthalide nanoemulsion preparation was proposed, that is, ultrasonic dispersion or rotary evaporation was used to prepare the complex, and then water-in-oil nanoemulsion was prepared, which significantly improved the encapsulation efficiency and stability of the 7-hydroxy-butylphthalide nanoemulsion preparation and solved the problem of the drugability of 7-hydroxy-butylphthalide.

[0026] (4) Using the modified rat stroke ischemia-reperfusion injury animal model, it was proposed that 7-hydroxy-butylphthalide nanoemulsion preparation has the ability to accelerate the recovery of nervous system function, reduce brain damage, and reduce the level of inflammatory factors, indicating that it has good efficacy and safety in treating stroke, providing a new agent for the treatment of stroke. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] FIG1 is a coarse-grained model of 7-hydroxy-butylphthalide in Example 2 of the present invention.

[0028] Figure 2 is a snapshot of the density distribution and trajectory of each component of the N3-LNE nanoemulsion system in Example 2 of the present invention; in the figure, (a)-(d), DOPC:PEG = 200:0, and the number of N3 molecules is 0, 20, 40, and 80, respectively; in (e)-(h), DOPC:PEG = 140:60, and the number of N3 molecules is 0, 20, 40, and 80, respectively.

[0029] Figure 3 is the radial distribution function of each component of the N3-LNE nanoemulsion system in Example 2 of the present invention; in the figure, in (a)-(d), DOPC:PEG = 200:0, the number of N3 molecules is 0, 20, 40, and 80, respectively; in (e)-(h), DOPC:PEG = 140:60, the number of N3 molecules is 0, 20, 40, and 80, respectively.

[0030] Figure 4 is an analysis diagram of the molecular action mechanism in the N3-LNE nanoemulsion system in Example 2 of the present invention; wherein, (a) a coarse-grained model of the N3-DOPC phospholipid complex structure; (b) and (c): radial distribution functions of N3 hydroxyl hydrogen and DOPC phospholipid phosphate groups, with molecular ratios of 1:1 and 2:1, respectively; (d) a curve showing how the distance between the DOPC alkyl group and the N3 aromatic ring structure changes with simulation time; (e) a curve showing how the distance between the DOPC alkyl group and the N3 alkyl structure changes with simulation time.

[0031] FIG5 is a diagram showing the solvent accessible surface area of ​​the N3-LNE nanoemulsion system in Example 2 of the present invention.

[0032] FIG6 is a DSC spectrum of the complex of five phospholipids and N3 in Example 3 of the present invention.

[0033] FIG7 is a DSC spectrum of the products obtained by three synthesis methods of 7-hydroxy-butylphthalide and PC-98T in Example 4 of the present invention.

[0034] FIG8 is a dose-effect graph showing the effects of HSPC and PC-98T on oil-water interfacial tension in Example 5 of the present invention; wherein: (a) LCT / water system; (b) MCT / water system; and (c) castor oil / water system.

[0035] FIG9 shows the neurological function scores of MCAO rats treated with excipients, NBP, and N3-LNE in Example 10 of the present invention, *P<0.05, n=8.

[0036] Figure 10 shows the Morris water maze evaluation results of each group of animals in Example 10 of the present invention; among them, A. the time required for positioning navigation to find the platform; B. the distance traveled for positioning navigation to find the platform; C. the time spent in the quadrant where the platform is located during spatial exploration; D. the number of times the platform is crossed during spatial exploration.

[0037] FIG11 is TTC staining of rat brain tissues in each group in Example 10 of the present invention.

[0038] FIG12 is TUNEL staining of rats in each group in Example 10 of the present invention.

[0039] FIG13 shows the inflammatory factor levels of rats in each group in Example 10 of the present invention.

[0040] FIG14 is a HE staining picture in Example 10 of the present invention. DETAILED DESCRIPTION

[0041] The present invention has developed a 7-hydroxy-butylphthalide nanoemulsion formulation containing a phospholipid PEG derivative. The molecular mechanism of action of 7-hydroxy-butylphthalide with phospholipids and phospholipid PEG derivatives in the new formulation is revealed through multi-scale computational simulation, providing theoretical guidance for the formulation design of the 7-hydroxy-butylphthalide nanoemulsion. The formulation specifications are determined by optimizing the formulation and preparation process. Furthermore, the effectiveness of the formulation in treating stroke is verified through in vivo animal pharmacodynamic evaluation, providing a reliable dosage form for clinical use. The innovative features of the present invention are as follows:

[0042] 1. One of the innovations of the present invention is that a 7-hydroxy-butylphthalide nanoemulsion preparation is proposed and its molecular interactions are revealed.

[0043] The present invention proposes to prepare a nanoemulsion preparation using 7-hydroxy-butylphthalide, applies multi-scale computational simulation to illustrate the molecular interactions between 7-hydroxy-butylphthalide and oils, phospholipids and PEG derivatives, and creatively proposes that the complex formed by 7-hydroxy-butylphthalide and phospholipids is the key to improving its solubility and drug loading, providing a theoretical basis for the formulation and process design of the nanoemulsion preparation using 7-hydroxy-butylphthalide.

[0044] 2. The second innovation of the present invention lies in the prescription and specifications of the 7-hydroxy-butylphthalide nanoemulsion preparation.

[0045] (1) Optimization of oils and phospholipids in nanoemulsions

[0046] The composition and proportion of oils in the formulation were optimized based on the solubility of 7-hydroxy-butylphthalide in oils, and the type of phospholipids was optimized based on the stability of the complex formed by 7-hydroxy-butylphthalide and phospholipids and the ability to improve the oil / water interfacial tension, ultimately obtaining a 7-hydroxy-butylphthalide nanoemulsion preparation with a high drug loading rate.

[0047] (2) Optimization of phospholipid PEG derivatives in nanoemulsions

[0048] The present invention proposes a prescription of adding a phospholipid PEG derivative into a 7-hydroxy-butylphthalide nanoemulsion preparation, thereby obtaining a new preparation with a more stable particle size and the ability to circulate for a long time in the body.

[0049] (3) Drug specifications of nanoemulsion preparations

[0050] The maximum specification of the 7-hydroxy-butylphthalide nanoemulsion preparation prepared by the present invention can reach 2.5 mg / mL, which is 10 times higher than the specification of 0.25 mg / mL of the butylphthalide preparation of the same drug on the market. It can be administered by intravenous injection, which is more conducive to meeting the requirements of emergency stroke treatment.

[0051] 3. The third innovation of the present invention lies in the preparation process of 7-hydroxy-butylphthalide nanoemulsion preparation.

[0052] In the preparation process of 7-hydroxy-butylphthalide nanoemulsion preparation, it is innovatively proposed to first use ultrasonic mixing or rotary evaporation process to prepare the complex of 7-hydroxy-butylphthalide and phospholipid, and then prepare the nanoemulsion preparation, thereby obtaining a 7-hydroxy-butylphthalide nanoemulsion preparation with good preparation stability and high encapsulation efficiency.

[0053] 4. The fourth innovation of the present invention is that the 7-hydroxy-butylphthalide nanoemulsion preparation has a high efficacy in treating stroke.

[0054] The modified rat ischemia-reperfusion model was used to verify the efficacy of the 7-hydroxy-butylphthalide nanoemulsion preparation proposed in the present invention with neurological function scores, Morris water maze, cerebral infarction rate, brain cell apoptosis, inflammatory factors, etc. as indicators, providing an effective new agent for the treatment of ischemic stroke.

[0055] The present invention is described in detail below with reference to specific examples.

[0056] Example 1, optimization of oil types in 7-hydroxy-butylphthalide nanoemulsion preparation.

[0057] (1) Experimental methods

[0058] Solubility of 7-hydroxybutylphthalide in individual oils: 2g of soybean oil (LCT), castor oil, isopropyl myristate (IPM), medium-chain triglycerides (MCT), olive oil, and sesame oil were placed in 15mL centrifuge tubes. An excess of 7-hydroxybutylphthalide was added and the mixture was shaken at room temperature (100 rpm) for 48 hours. After equilibration, the mixture was centrifuged (4500 rpm for 15 minutes). An appropriate amount of the saturated solution was filtered through a 0.22μm filter and diluted. The solubility of 7-hydroxybutylphthalide in the various oils was determined by HPLC. HPLC conditions: Column: Phenomenex ODS-C18 column (2cm×22cm); Measurement temperature: 25°C; Mobile phase: acetonitrile-water (60:40, v / v); Flow rate: 1.0mL / min; Injection volume: 10μL; Detection wavelength: 300nm.

[0059] Solubility of 7-hydroxy-butylphthalide in mixed oils: LCT and MCT, castor oil and MCT were mixed at a ratio of 1:1, 1:2, 1:3, or 1:4 (w / w), and an excess of 7-hydroxy-butylphthalide was added. The solubility of 7-hydroxy-butylphthalide in the mixed oils was determined using the same assay method as above.

[0060] (2) Experimental results

[0061] The solubility of 7-hydroxybutylphthalide (N3) in individual oils and fats determined by HPLC is shown in Table 1. In Table 1, n=3 indicates triplicate experiments; the same applies below. As shown in Table 1, the solubility of 7-hydroxybutylphthalide in individual oils and fats is ranked from highest to lowest: castor oil > MCT > IPM > sesame oil > olive oil > LCT. LCT provides energy and is commonly used as an intravenous nutrient, but 7-hydroxybutylphthalide has a low solubility in it. MCT has high solubility in blood, is easily absorbed and metabolized, and has minimal liver damage, so 7-hydroxybutylphthalide has a high solubility in it. Olive oil, rich in unsaturated fatty acids and natural antioxidants like vitamin E, significantly reduces lipid peroxidation, but 7-hydroxybutylphthalide has a low solubility in it. Castor oil has a strong ability to dissolve 7-hydroxybutylphthalide, but also has a high viscosity. Therefore, LCT, MCT, and castor oil were selected as alternative oils for compounding.

[0062] Table 1. Solubility of 7-hydroxybutylphthalide in single oils (n=3)

[0063] The solubility of 7-hydroxy-butylphthalide (N3) in the mixed oil was determined by HPLC, as shown in Table 2. It can be seen that in the mixed oil, the solubility of N3 is approximately the weighted average of the solubility in the two oils, indicating that the oil mixing basically does not affect the solubility of N3.

[0064] Table 2. Solubility of 7-hydroxybutylphthalide in mixed oils (n=3)

[0065] As can be seen from the above, LCT, MCT and castor oil are preferred as oils in 7-hydroxy-butylphthalide nanoemulsion preparations, and they can be used alone or in combination.

[0066] Example 2, molecular interactions in 7-hydroxy-butylphthalide nanoemulsion formulation.

[0067] (1) Experimental methods

[0068] Packmol, GROMACS 5.1.4, and Gaussian 16 10 By studying the molecular interactions between drugs and carriers in 7-hydroxy-butylphthalide nanoemulsions (N3-LNE for short), the authors elucidated the modes of action between the various components in the nanoemulsions and the drug N3, providing guidance and theoretical basis for prescription optimization.

[0069] ① Coarse-grained simulation: The study system consists of soybean oil (LCT), dioleoylphosphatidylcholine (DOPC), distearoylphosphatidylethanolamine-polyethylene glycol (DSPE-PEG, abbreviated as PEG), and 7-hydroxybutylphthalide (abbreviated as N3). The coarse-grained models of LCT, DOPC, and PEG were constructed based on previous studies (references: Ma Shuang. Multiscale computational simulation of molecular interactions and transmembrane transport mechanisms in lipid emulsions and dual-mediated liposomes [Master's thesis]. Beijing: Peking University, 2020; Deng Bo. Molecular interaction mechanisms in RVGP and R9 dual-modified liposomes [Master's thesis]. Beijing: Peking University, 2019). The supplementary force field parameters for the N3 coarse-grained model were generated based on mapping from a non-hydrogen all-atom model. The specific atomic partitioning is shown in Figure 1.

[0070] The simulation box was set as a 25 nm cube. LCT, DOPC, PEG, and N3 drug molecules were added to the box according to the system designed in Table 3. 29,959 water molecules were then added to the simulation box. CGMD simulations were performed using the GROMACS 5.1.4 software package under the Martini force field, with a time step of 8 fs and a total simulation time of 60 ns. Periodic boundary conditions were used at a constant temperature of 298 K and a 3×10 -4 bar -1 Under the constant pressure (NPT) ensemble, the V-rescale temperature coupling algorithm and the isotropic Berendsen pressure coupling algorithm are used to couple the temperature and pressure, respectively. The temperature and pressure coupling constants are τ T =1.0ps and τ P = 3.0 ps. After the system energy converged to a stable conformation, trajectory analysis was performed and the conformation was observed using VMD (v1.9.3, America). The structure, molecular presence, and stability of the self-assembled system were analyzed using the potential energy changes, the density distribution function of each molecule, the radial distribution function, and the solvent accessible surface area (SASA).

[0071] Table 3. Molecular number of each component in the DOPC-LCT-PEG system

[0072] ② All-atom simulation: The research system consists of three molecules: DOPC, N3 and LCT, with a ratio of 1:1:94 and 1:2:93 respectively. The geometric structures of the three small molecules were optimized using Gaussian 16 software, and RESP (restraint electrostatic potential) atomic charges were calculated. The GAFF2 (generalized AMBER) molecular force field was generated using the AMBER built-in antechamber tool. A 50 ns dynamics simulation was performed for each system using the PMEME.CUDA (Particle Mesh Ewald Molecular Dynamics) module of the AMBER 18 software package. The radial distribution functions of the different components of the system were calculated with the center of the nanoemulsion as the coordinate origin. The molecular interactions between the N3 molecule and DOPC and LCT were analyzed by analyzing the intermolecular hydrogen bonds and van der Waals forces of each component.

[0073] (2) Experimental results

[0074] The density distribution of each component of the simulation system is shown in Figure 2. The results show that: the components in the system are symmetrically distributed, indicating that the system can autonomously form a stable, compact spherical structure with a particle size of approximately 16 nm; the water distribution rate is low at the center of the spherical particles, while the LCT and N3 distribution rates are high; the water distribution rate is high on the outside while the LCT and N3 distribution rates are low, indicating that the interior of the formed spherical particles is a hydrophobic area (oil phase) and the outside is a hydrophilic area (water phase); the density distribution curve of DOPC is located outside LCT and N3, indicating that the fatty chains in DOPC are inserted into the sphere, while the hydrophilic choline is distributed on the outer surface of the sphere.

[0075] In the PEG-free system (Figure 2 (a)-(d)), the N3 density distribution coincides with LCT, and as the number of drug N3 molecules increases, the number distributed inside the sphere increases, indicating that the molecular interaction between N3 and soybean oil is the main factor for drug loading; but in the system with PEG (DOPC:PEG = 140:60) (Figure 2 (e)-(h)), as the number of N3 molecules increases, the radial distribution curve of N3 gradually shifts outward until its number reaches 80, at which point its distribution curve breaks through the outer boundary of DOPC and is distributed in the aqueous phase. It can be clearly seen from the VMD conformational image that some N3 molecules are dispersed outside the spherical particles, indicating that the presence of PEG reduces the drug loading capacity of N3 in the nanoemulsion.

[0076] To further elucidate why the presence of PEG reduces N3 drug loading, we analyzed the radial distribution functions (RDFs) of each component, with the center of the nanoemulsion as the coordinate origin, as shown in Figure 3. As can be seen in Figure 3, LCT, DOPC, and N3 all exhibit bimodal peaks, which is related to the use of the "center of mass" as a representative molecule for statistical analysis. In the PEG-free system (Figures 3(a)-(d)), the proportion of N3 molecules distributed in the "inner layer" (i.e., within a radius of 0 to 4 nm) of the spherical particle is higher than that in the "outer layer," especially as the number of N3 molecules increases. However, in the PEG-containing system (Figures 3(e)-(h)), the proportion of N3 molecules in the "outer layer" is higher than that in the "inner layer," resulting in a significant outward shift, making N3 more likely to escape from the nanoemulsion and reducing drug loading. This is attributed to the partial replacement of DOPC by DSPE-PEG in the system, likely due to some interaction between N3 and DOPC. The reduced number of DOPC molecules leads to a decrease in N3 drug loading. Therefore, all-atom simulation is still needed to conduct an in-depth analysis of the molecular interaction between N3 and DOPC.

[0077] A coarse-grained model of the DOPC-N3 complex was constructed based on the coarse-grained model, as shown in Figure 4 (a). It can be seen that the polar bead SO2 representing the double-bonded hydroxyl group in the N3 molecule is close to the phospholipid head, and it is speculated that there may be hydrogen bond interactions between the corresponding groups; the hydrophobic bead CO1 representing the alkane chain in the N3 molecule is close to the hydrophobic tail of the phospholipid, and it is speculated that there may be van der Waals forces between the corresponding groups.

[0078] On this basis, all-atom dynamics simulations were used to further elucidate the formation mechanism of the complex structure. Radial distribution functions (Figure 4(b)-(c)) indicate that the hydroxyl hydrogen of N3 forms stable hydrogen bonds with the choline amino group of DOPC, and that one DOPC molecule can form a stable complex with the hydroxyl hydrogens of two N3 molecules through hydrogen bonding. Furthermore, the distances between the DOPC alkyl group and the N3 aromatic ring, as well as between the DOPC alkyl group and the N3 alkyl group, remain stable over simulation time, indicating weak van der Waals interactions between the aromatic group of N3 and the alkyl group of DOPC (Figure 4(d)-(e)).

[0079] To further analyze the effect of PEG addition on the stability of the system, the solvent accessible surface area (SASA) of the entire spherical particles and LCT was analyzed, as shown in Figure 5. The results showed that the addition of PEG increased the SASA of the entire spherical particles, indicating that the stability of the system increased and it was not easy to aggregate. This may be related to the hydration ability of PEG, further illustrating the necessity of adding PEG to the formulation.

[0080] Comparing the systems with and without PEG, there was no significant change in the SASA of LCT, indicating that the addition of PEG did not affect the interaction between LCT and the solvent. This may be related to the protective effect of phospholipid molecules on LCT. The number of phospholipid hydrophobic groups in the two systems was consistent, and their effects on the SASA of LCT were consistent.

[0081] Therefore, in the N3-LNE preparation, N3 and phospholipid molecules form a complex through hydrogen bonds and van der Waals forces, allowing N3 to be efficiently encapsulated in the nanoemulsion; the addition of phospholipid PEG derivatives makes the nanoemulsion system more stable, but there is a risk of reducing the N3 drug encapsulation efficiency. The amount of phospholipid PEG derivatives added needs to be selected after balancing the encapsulation efficiency and stability.

[0082] Example 3, optimization of phospholipid types in 7-hydroxy-butylphthalide-phospholipid complex.

[0083] In Example 2, it was proposed that 7-hydroxy-butylphthalide and phospholipids can form a complex, and the molar ratio of the two can be 2:1. To further verify the existence of the complex and optimize the type of phospholipid that can form a stable 7-hydroxy-butylphthalide phospholipid complex, this example uses differential scanning calorimetry to study the thermal effect of the complex formed by 7-hydroxy-butylphthalide and phospholipids. By comparing the DSC spectra and related thermodynamic parameters of the complex with 7-hydroxy-butylphthalide and phospholipids, the type of phospholipid is optimized using significant phase transition temperature and phase transition enthalpy as indicators.

[0084] (1) Experimental methods

[0085] N3 and a phospholipid solution were prepared separately in ethanol at a 2:1 (mol / mol) ratio. The phospholipids were selected from dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylethanolamine (DSPE), hydrogenated distearoylphosphatidylcholine (HSPC), egg yolk phosphatidylglycerol (EPG), and egg yolk phosphatidylcholine (PC-98T). The mixed solution was pre-frozen at -20°C overnight and then freeze-dried under vacuum to obtain a solid. The resulting solid was then removed and ground uniformly. 6-8 mg was added to a crucible of a differential scanning calorimeter (DSC) and the temperature was programmed at a rate of 10°C / min over a temperature range of 25°C to 150°C. DSC spectra were collected. Appropriate amounts of N3 and phospholipids were taken for DSC measurement, and the spectra, phase transition temperatures and phase transition enthalpies of the N3 and phospholipid complexes were compared. The types of phospholipids in the 7-hydroxy-butylphthalide-phospholipid complex were optimized based on the significant changes in the phase transition temperature and phase transition enthalpy.

[0086] (2) Experimental results

[0087] Comparing the DSC graphs of N3, phospholipids and the complex of N3 and phospholipids, as shown in Figure 6, the phase transition temperature T sAs shown in Table 4, the phase transition enthalpy ΔH of the freeze-dried product of DSPE and N3 shows a double peak, and the phase transition peak of N3 is still retained, indicating that N3 and DSPE cannot form a complex; while EPG, PC-98T, DPPC, and HSPC can form complexes with N3, and the phase transition temperature is lower than that of N3. The phase transition peaks of these phospholipids disappear, and the phase transition enthalpy of the complex is lower than that of N3. Among them, the phase transition enthalpy of the complex formed by HSPC and PC-98T with N3 is significantly reduced, indicating that the complex formed by HSPC and PC-98T with N3 is more stable.

[0088] Table 4. Phase transition parameters of N3, phospholipids and their freeze-dried products (n=3)

[0089] As can be seen from the above, differential scanning calorimetry technology verified that N3 and choline phospholipids can form complexes, which is consistent with the conclusion of Example 2; among them, the complexes formed by HSPC and PC-98T with N3 are more stable.

[0090] Example 4, synthesis process of complex formed by N3 and phospholipid.

[0091] (1) Experimental methods

[0092] Taking PC-98T as an example, solid 1 was obtained by physically mixing N3 and PC-98T solids in a 2:1 (mol / mol) ratio. Separate N3 and PC-98T solutions were prepared in ethanol and mixed in a 2:1 (mol / mol) ratio of N3 to phospholipid. The mixed solution was pre-frozen overnight at -20°C and then freeze-dried under vacuum to obtain solid 2. The mixed solution was rotary evaporated at 50°C and 200 rpm to obtain solid 3. Differential scanning calorimetry (DSC) was performed on 6-8 mg of solid samples 1-3 in a DSC crucible with a temperature program of 10°C / min over a temperature range of 25°C to 150°C. The effects of physical mixing, freeze-drying, and rotary evaporation on complex formation were analyzed by comparing DSC spectra and related thermodynamic data.

[0093] (2) Experimental results

[0094] The DSC spectra of the solid samples obtained by N3 and the three processes are shown in Figure 7. The phase transition temperature T s The phase transition enthalpy ΔH is shown in Table 5. It can be seen that the physical mixture spectrum and thermodynamic data are similar to those of N3, indicating that the two cannot form a complex by heating, but can form a complex by ultrasonic dissolution or rotary evaporation of the two in ethanol.

[0095] Table 5. Phase transition parameters of solid samples obtained by N3 and three processes

[0096] Therefore, after N3 and PC-98T were prepared into a solution in ethanol, the complex could be prepared by two processes: ultrasonic dissolution and freeze drying and vacuum rotary evaporation.

[0097] Example 5, optimization of the type of phospholipid emulsifier in 7-hydroxy-butylphthalide nanoemulsion preparation.

[0098] (1) Experimental methods

[0099] Phospholipids act as emulsifiers in nanoemulsions, reducing oil / water interfacial tension and improving nanoemulsion stability. To further optimize the type of phospholipid used as an emulsifier in nanoemulsions, an interfacial tensiometer was used to investigate the ability of two phospholipids, PC-98T and HSPC, to improve oil / water interfacial tension. The oils were selected from LCT, MCT, and castor oil.

[0100] Using chloroform as the solvent, a 1 mg / mL phospholipid solution was accurately prepared. The phospholipids were selected from PC-98T and HSPC. At room temperature, the platinum plate of the interfacial tensiometer was placed in air and zeroed. 40 mL of ultrapure water was added to the sample chamber. The sample stage was raised so that the platinum plate was approximately 3 mm below the liquid surface. The stage was then slowly lowered until the bottom edge of the platinum plate was just level with the liquid surface. Using a pipette, oil was added to the water surface until the platinum plate was completely submerged. The interfacial tension was recorded. Carefully add 1 μL of the phospholipid solution to the oil / water interface. Once the value stabilized, the interfacial tension was recorded. This procedure was repeated until the interfacial tension no longer decreased significantly with increasing phospholipid addition. A dose-response curve for the effect of phospholipid on the oil / water interfacial tension was constructed, and the minimum amount of phospholipid required to reduce the interfacial tension to the equilibrium point was calculated. A lower phospholipid dosage indicates a stronger emulsifying ability and a lower interfacial tension at equilibrium, indicating a more stable nanoemulsion.

[0101] (2) Experimental results

[0102] The interfacial tension between oil and water is shown in Table 6. It can be seen that the interfacial tension of castor oil / water is the smallest, followed by MCT / water, and the interfacial tension of LCT / water is the largest.

[0103] Table 6. Surface tension of phospholipids and oils (n=3)

[0104] The dose-response relationship of the effect of phospholipids on oil / water interfacial tension is shown in Figure 8 and Table 7. Compared with HSPC, PC-98T can reduce the interfacial tension of both LCT / water and MCT / water to approximately zero, and this is achieved at a significantly lower dosage. This indicates that PC-98T is more effective than HSPC in improving interfacial tension. In the castor oil / water system, although PC-98T reduced the interfacial tension to a minimum of 3.03 mN / m, this was achieved at a relatively low dosage. Therefore, PC-98T is a more effective emulsifier in nanoemulsion formulations, significantly improving the stability of the nanoemulsion.

[0105] Table 7. Minimum value of phospholipids in reducing oil / water interfacial tension and their dosage

[0106] As can be seen from the above, PC-98T can significantly reduce the oil / water interfacial tension in nanoemulsion preparations and significantly improve the stability of nanoemulsions, making it a good nanoemulsion emulsifier. Combined with Examples 3 and 5, it can be seen that PC-98T can not only form a stable complex with N3, but also significantly reduce the oil / water interfacial tension of nanoemulsions. Therefore, it is an important component in the formulation of 7-hydroxy-butylphthalide nanoemulsions.

[0107] Comparative Example 1, 1.0 mg / mL 7-hydroxy-butylphthalide nanoemulsion preparation with low oil concentration (1%).

[0108] Preparation process: Dissolve N3 in an appropriate amount of anhydrous ethanol, then add medium-chain triglycerides (MCT), soybean oil (LCT), oleic acid, and PC-98T in sequence to obtain a clear oil phase. Add water for injection to a clean small beaker, then add F68 and glycerin. Ultrasonicate until clear to obtain an aqueous phase. While still hot, rapidly add the aqueous phase to the oil phase in a cell disruptor (180W, 40 min, 10 s / cycle). Disintegrate until the solution is a uniform milky white. Make up to volume with water for injection. The formulation is shown in Table 8 below.

[0109] Table 8 Low oil concentration (1%) 1.0 mg / mL 7-hydroxy-butylphthalide nanoemulsion formulation

[0110] Example 6, 1.0 mg / mL 7-hydroxy-butylphthalide nanoemulsion preparation with high oil concentration (10%).

[0111] Preparation process: PC-98T and N3 are prepared in ethanol to 250 mg / mL and 333 mg / mL stock solutions, respectively. After ultrasonically mixing the prescribed amounts of both, medium-chain triglycerides (MCT), soybean oil (LCT), and oleic acid are added to the mixture to obtain a clear oil phase. Water for injection is measured and placed in a clean small beaker. The prescribed amounts of F68 and glycerin are then added, followed by heating and stirring to dissolve until clear, producing an aqueous phase. The aqueous phase is quickly added to the oil phase and vortexed to produce a crude emulsion. The solution is then sheared in a cell disruptor (180W, 40 min, 10 s / cycle) until a uniform milky white solution is achieved. The solution is then brought to volume with water for injection. The formulation is shown in Table 9 below.

[0112] Table 9 Prescription of 1.0 mg / mL 7-hydroxy-butylphthalide nanoemulsion formulation with high oil concentration (10%)

[0113] The N3-LNE preparations of Comparative Example 1 and Example 6 were prepared respectively. The physical and chemical properties of the two preparations were measured after 1, 4 and 7 days using the following experimental methods to analyze the quality and stability of the preparations.

[0114] (1) Detection method

[0115] ① Determination of N3-LNE particle size

[0116] The N3-LNE preparation sample was filtered through a 0.22 μm filter membrane and diluted 100 times with water for injection. After being added to the sample cell, the particle size of the sample was measured using a laser scattering particle size analyzer. The temperature was set to 25°C, the sample was equilibrated for 20 seconds, and 20 cycles were performed. The average value was obtained after 3 measurements.

[0117] ②N3 drug content determination

[0118] Take 100 μL of the prepared N3-LNE, add nine times the volume of methanol to break the emulsion, dilute it 4 times with the mobile phase, pass it through a 0.22 μm filter membrane, and then detect it by HPLC to obtain the peak area and retention time, which are substituted into the standard curve to calculate the drug concentration.

[0119] HPLC chromatographic conditions: chromatographic column: Phenomenex ODS-C18 column (2 cm × 22 cm); measurement temperature: 25 ° C; mobile phase: acetonitrile-water (60:40, v / v); flow rate: 1.0 mL / min; injection volume: 10 μL; detection wavelength: 300 nm.

[0120] ③N3-LNE encapsulation efficiency determination

[0121] 500 μL of the N3-LNE preparation was added to a Sephadex G-50 column (2 cm × 22 cm). The column was eluted with ultrapure water at a flow rate of 1.0 mL / min. 10–30 mL of the eluate was collected as the nanoemulsion fraction, and 40–65 mL as the free drug fraction. Appropriate amounts of each eluate were collected, methanol was added, and the N3 drug concentration was determined by HPLC. The experiment was repeated three times. The encapsulated efficacy (ee%) was calculated according to the following formula:

[0122] Encapsulation efficiency:

[0123] Where: C1 is the N3 concentration in the nanoemulsion; C2: the free N3 concentration; V1: the volume of the nanoemulsion eluate; V2: the volume of the free drug eluate.

[0124] (2) Experimental results

[0125] Table 10 shows the particle size, polydispersity coefficient, and encapsulation efficiency data for the N3-LNE formulations in Comparative Example 1 and Example 6 after 1, 4, and 7 days of storage. The results show that the particle size of both formulations was approximately 200 nm. The encapsulation efficiency of the N3-LNE formulation with a low oil concentration (1%) was less than 80%, and significant crystallization appeared on the bottle wall on days 4 and 7. Microscopic examination revealed square crystal structures, indicating that N3 was unstable in the formulation and crystallization occurred. The encapsulation efficiency of the N3-LNE formulation with a high oil concentration (10%) was greater than 80%, meeting the encapsulation efficiency requirements for nanoformulations. Microscopic examination revealed that the formulation in Example 6 showed no crystallization after 7 days of storage. These comparative results demonstrate that the stability and N3 solubility of the formulation in Example 6 are significantly superior to those in Comparative Example 1.

[0126] Table 10 Characterization of N3-LNE preparations with different oil concentrations (n=3)

[0127] Advantages of Example 6 over Comparative Example 1: Compared with Comparative Example 1, the beneficial effects of Example 6 are derived from the difference in oil concentration. As shown in Example 1, the solubility of N3 in LCT / MCT (1:3) is 28 μg / mg. Therefore, when the oil concentration is 1%, the theoretical maximum N3 loading in a 5mL formulation is 1.4 mg, which is lower than the prescribed N3 dosage of 5 mg. In other words, to produce a 1mg / mL N3-LNE nanoemulsion formulation, the theoretical minimum oil concentration is 5%. Increasing the oil concentration to 10% is the main reason for the high encapsulation efficiency of the N3-LNE formulation described in Example 6. Generally, the concentration of fat emulsion as an enteral nutrient base can reach up to 30%. Therefore, in the N3-LNE nanoemulsion formulation, the oil concentration ranges from 5% to 30%, preferably 10%.

[0128] Example 7, Optimization of the preparation process of N3-LNE preparation.

[0129] As shown in Examples 2, 3, and 4, N3 can form complexes with phospholipids, preferably PC-98T. To demonstrate the importance of complexes for the quality and stability of N3-LNE formulations, this Example optimizes the N3-LNE preparation process. Based on a comparison between Example 6 and Comparative Example 1, this Example 7 uses the same formulation ratio as Example 6, namely, a 1.0 mg / mL 7-hydroxy-butylphthalide nanoemulsion formulation with a high oil concentration (10%) as described in Table 9.

[0130] (1) Experimental methods

[0131] Process 1 (direct mixing): Dissolve N3 in an appropriate amount of anhydrous ethanol, then add medium-chain triglycerides (MCT), soybean oil (LCT), PC-98T, and oleic acid in that order to obtain a clear oil phase. Measure water for injection into a clean small beaker, add F68 and glycerin in that order, and dissolve until clear to obtain an aqueous phase. While still hot, rapidly add the aqueous phase to the oil phase in a cell disruptor (180W, 40 min, 10 s / cycle). Disintegrate until the solution is a uniform milky white color, and then adjust to volume with water for injection.

[0132] Process 2 (ultrasonic dispersion): PC-98T and N3 are prepared in ethanol to a stock solution of 250 mg / mL and 333 mg / mL, respectively. The prescribed amounts of the two are mixed and ultrasonically mixed until uniform. The prescribed amounts of medium-chain triglycerides (MCT), soybean oil (LCT), and oleic acid are added to the mixture to obtain a clear oil phase. Water for injection is measured and added to a clean small beaker. The prescribed amounts of F68 and glycerin are added in sequence and dissolved until clear to obtain an aqueous phase. The aqueous phase is quickly added to the oil phase and vortexed to produce a crude emulsion. The solution is then sheared at high speed in a cell disruptor (180W, 40 minutes, 10 seconds / cycle) until a uniform milky white solution is obtained. The solution is then brought to volume with water for injection.

[0133] Process 3 (rotary evaporation): PC-98T and N3 are prepared separately in ethanol to form mother solutions. The mixture is mixed according to the prescribed amount and then rotary evaporated to remove the ethanol. The prescribed amounts of medium-chain triglycerides (MCT), soybean oil (LCT), and oleic acid are added to the solution to obtain a clear oil phase. Water for injection is measured and added to a clean small beaker. The prescribed amounts of F68 and glycerin are then added, followed by heating and stirring to dissolve until clear, producing an aqueous phase. The aqueous phase is quickly added to the oil phase and vortexed to produce a crude emulsion. The solution is then sheared in a cell disruptor (180W, 40 minutes, 10 seconds per cycle) until it becomes a uniform milky white. The solution is then brought to volume with water for injection.

[0134] The formulas for preparing N3-LNE by the above three processes are consistent, as shown in Table 9.

[0135] (2) Experimental results

[0136] According to the detection method described in Example 6, the particle size, polydispersity index, and encapsulation efficiency of N3-LNE preparations obtained by the three preparation processes were measured after 1, 4, and 7 days of storage. Table 11 shows the results. The particle size of N3-LNE obtained by all three preparation processes was approximately 200 nm. The encapsulation efficiency of N3-LNE prepared by ultrasonic dispersion and rotary evaporation was above 80%, and the preparations exhibited good shelf stability. As described in Example 4, ethanolic solutions of phospholipids and N3 formed relatively stable complexes upon ultrasonic or rotary evaporation, which is the primary reason for the improved stability of the N3-LNE preparations. In comparison, the encapsulation efficiency of N3-LNE prepared by the direct mixing method was less than 80% on day 7, likely due to the inability of the phospholipids to form complexes with the drug.

[0137] Table 11 Characterization of N3-LNE preparations prepared by three processes (n=3)

[0138] Comparing the operability of the preparation processes, rotary evaporation has higher requirements on equipment, while ultrasonic dispersion is simple and easy to operate and suitable for industrial production. Therefore, ultrasonic dispersion is preferred.

[0139] Example 8, Preparation and formulation of 1.0 mg / mL N3-LNE containing DSPE-PEG2000.

[0140] As described in Example 2, the addition of phospholipid PEG derivatives to the nanoemulsion facilitates the formation of a hydration layer on its surface, improves the stability of the formulation, and is prone to immune escape in the body after injection, resulting in long-term circulation, allowing more nanoemulsions to reach the target tissue and exert their efficacy. However, the amount of phospholipid PEG derivatives also has the risk of reducing the N3 encapsulation efficiency in the nanoemulsion. Therefore, this example uses distearoylphosphatidylethanolamine-polyethylene glycol 2000 (DSPE-PEG2000) as an example to examine the dosage range of DSPE-PEG2000 in the nanoemulsion, providing a more stable 7-hydroxy-butylphthalide nanoemulsion formulation.

[0141] (1) Experimental methods

[0142] Preparation process: PC-98T and N3 are prepared in ethanol to 250 mg / mL and 333 mg / mL stock solutions, respectively. The prescribed amounts of PC-98T and N3 are mixed and sonicated until uniformly mixed. The prescribed amounts of medium-chain triglycerides (MCT), soybean oil (LCT), oleic acid, and DSPE-PEG2000 are added to the mixture to obtain a clear oil phase. Water for injection is measured and added to a clean small beaker. The prescribed amounts of F68 and glycerin are added in sequence. Heat and stir to dissolve until clear, producing an aqueous phase. The aqueous phase is quickly added to the oil phase and vortexed to produce a crude emulsion. The solution is then sheared in a cell disruptor (180W, 40 min, 10 s / cycle) until a uniform milky white solution is achieved. The solution is then brought to volume with water for injection. Tables 12-14 below provide three formulations with varying DSPE-PEG2000 concentrations.

[0143] Table 12 Prescription 1 (N3-LNE containing 0.025% DSPE-PEG2000)

[0144] Table 13 Prescription 2 (N3-LNE containing 0.1% DSPE-PEG2000)

[0145] Table 14 Prescription 3 (N3-LNE containing 0.25% DSPE-PEG2000)

[0146] (2) Experimental results

[0147] According to the detection method described in Example 6, the particle size, polydispersity index, and encapsulation efficiency of the N3-LNE formulation to which DSPE-PEG2000 was added were measured after 1, 4, and 7 days, as shown in Table 15. The results show that compared with the N3-LNE formulation without DSPE-PEG2000, the particle size of the formulation after the addition of DSPE-PEG2000 was reduced and the PDI was significantly reduced, indicating that DSPE-PEG2000 is beneficial for improving the uniformity of the formulation and the encapsulation efficiency is increased, indicating that the addition of DSPE-PEG2000 improves the stability of the formulation.

[0148] Table 15 Characterization of N3-LNE formulations with different DSPE-PEG concentrations (n=3)

[0149] From the above, it can be seen that the DSPE-PEG2000 concentration in the N3-LNE preparation within the range of 0.025-0.25% is beneficial to improving the stability and encapsulation efficiency of the preparation.

[0150] Example 9 Preparation and Formulation of 2.5 mg / mL N3-LNE Formulation

[0151] (1) Experimental methods

[0152] Preparation: PC-98T and N3 were prepared in ethanol to a stock solution of 250 mg / mL and 333 mg / mL, respectively. The prescribed amounts of PC-98T and N3 were mixed and sonicated until uniformly mixed. The prescribed amounts of medium-chain triglycerides (MCT), soybean oil (LCT), oleic acid, and DSPE-PEG2000 were then added to the mixture to obtain a clear oil phase. Water for injection was measured and placed in a clean small beaker. The prescribed amounts of F68 and glycerol were then added, followed by heating and stirring to dissolve until clear, producing an aqueous phase. The aqueous phase was quickly added to the oil phase and vortexed to produce a crude emulsion. The solution was then sheared in a cell disruptor (180W, 40 min, 10 s / cycle) until a uniform milky white solution was achieved. The volume was then adjusted to volume with water for injection. The formulation is shown in Table 16 below.

[0153] Table 16

[0154] (2) Experimental results

[0155] The particle size, polydispersity index, and encapsulation efficiency of the 2.5 mg / mL N3-LNE formulation of this example were measured using the detection method described in Example 6 after 1, 4, and 7 days of storage, as shown in Table 17. The results show that the particle size of this formulation is approximately 300 nm, indicating good dispersibility, and the encapsulation efficiency meets the requirements for nanoformulations. Compared with Example 8, this example further increases the N3 content in the nanoemulsion.

[0156] Table 17 Characterization of 2.5 mg / mL N3-LNE Formulation (n=3)

[0157] Therefore, the above-mentioned 7-hydroxy-butylphthalide nanoemulsion (N3-LNE) increases the solubility of 7-hydroxy-butylphthalide to 2.5 mg / mL. According to the patient's clinical dosage of 250 mg / 60 kg, the injection volume can be reduced to 10 mL, meeting the intravenous push volume requirement, and has good clinical application prospects.

[0158] Example 10, efficacy and safety evaluation of N3-LNE preparation.

[0159] (1) Experimental methods

[0160] ① Establishment of rat cerebral ischemia-reperfusion model (MCAO): SD rats (230g-260g) were anesthetized and fixed, the common carotid artery of the rats was isolated, and a suture plug was inserted according to the marking point method. Postoperative treatment was performed and reperfusion was performed 1.5 hours later.

[0161] ② Dosage regimen and grouping

[0162] Rats (♂, 230 g-260 g) were divided into sham, model (MCAO), excipient (LNE), butylphthalide (NBP), and N3-LNE groups, with 6 rats in each group. 1.5 h after the MCAO model was established, the rats were given a tail vein bolus injection of 5 mg / kg at a rate of 0.5 mL / min. The drug was administered within 10 min, and then the suture was removed to restore blood perfusion. An equal volume of drug was administered to each group.

[0163] ③ Neurological function evaluation

[0164] The mNSS score is used as a standard for evaluating neurological function, including motor, sensory, balance, and reflex tests. An mNSS score of 0 represents normal, while 18 indicates severe impairment. Twenty-four hours after modeling and drug administration, rats were tested for experimental items. Modeling was considered successful when the rat's mNSS score was ≥6.

[0165] ④Morris water maze

[0166] The water maze is divided into four quadrants, with the platform placed in the first quadrant. During training, rats were placed at four starting points in the pool, and the time was set for 60 seconds. The training ended when the rats reached the platform and stayed on it for more than 10 seconds. If the platform was not found within 60 seconds, the rats were guided to the platform and stayed there for 10 seconds, and then the training ended. The training lasted for 5 days, with each rat training four times a day. On the 6th day, the rats were randomly divided into groups, underwent stroke surgery, and completed drug administration. 24 hours after drug administration, positioning navigation and spatial exploration experiments were conducted.

[0167] ⑤TTC staining: 24 hours after administration, the rats were deeply anesthetized and the brain tissue was removed. The brain tissue was washed and pre-frozen. The rat brain tissue was sliced ​​from the olfactory bulb into 6-8 slices with a thickness of approximately 2 mm. The slices were placed in 0.5% TTC solution and stained in the dark at 37°C for 20 minutes. After removal, they were fixed with 4% paraformaldehyde and stored in the dark. After the brain slices were fixed for 24 hours, the white infarct part and the red normal tissue part were separated. The weight of the white part and the total weight were weighed to calculate the rat cerebral infarction rate.

[0168] ⑥TUNEL staining: 24 h after administration, rats were heavily anesthetized and sacrificed. The intact brain tissue was dissected and frozen at -20°C for 20 min. The brain tissue was cut into 5-6 μm sections along the coronal plane and stained according to the instructions of the TUNEL kit. The images were scanned using a Pannoramic MIDI basic pathological section scanner with a DAPI detection wavelength of 454 nm and a dUTP detection wavelength of 515 nm. ImageJ software was used to count the number of intact cell nuclei and apoptotic cells, and the percentage of apoptosis was calculated.

[0169] ⑦ Elisa method for determination of the content of inflammatory factors in the right brain: 24 hours after administration, the rats were anesthetized and killed, and the brain tissue was removed, washed with physiological saline, weighed, placed in an EP tube, and stored for later use; pre-cooled PBS was added at a volume ratio of 1:9, and the mixture was ground using a freezing grinder. After centrifugation, the content of inflammatory factors such as IL-1β, IL-6, TNF-α, and IL-3 was determined according to the method in the ELISA kit instructions.

[0170] ⑧HE staining: 24 hours after administration, rats were anesthetized and killed, and the heart, liver, spleen, lung, and kidney tissues were dissected and separated for HE staining to evaluate the safety of the preparation.

[0171] (2) Experimental results

[0172] ① Neurological score results: The neurological score results of rats in each group after cerebral ischemia-reperfusion are shown in Figure 9. As shown in Figure 9, the model success rate is 100%, which can be used for drug pharmacodynamic evaluation. The new 7-hydroxy-butylphthalide formulation can effectively improve the behavior and neurological function of animals after cerebral ischemia-reperfusion.

[0173] ② Morris water maze behavioral study: The Morris water maze test of animals in each group after cerebral ischemia-reperfusion is shown in Figure 10. Compared with the sham group, the total positioning navigation time (t PN) and path (The distance traveled by positioning navigation, d) increased significantly (p < 0.05), and the frequency of crossing platform (f CP ) was significantly reduced (p<0.05), and the staying time in the quadrant of the platform (t S ) decreased, indicating that the learning and memory ability of the MCAO group was significantly reduced after brain injury, and the group lacked the awareness of finding the target, and the model was successfully established; (2) Compared with the MCAO group, the NBP and N3-LNE groups t PN and l decreased, t S and f CP There was an increase, but due to the large deviation of the data, there was no significant difference.

[0174] ③TTC staining: TTC staining was performed on each group of animals, and the degree of brain damage was assessed using the infarction rate (CI%), as shown in Figure 11. The results showed that the brain tissue of rats in the sham group stained red with TTC, indicating that CCA ligation did not damage the brain tissue. Rats in the MCAO group showed extensive necrosis in the right brain tissue, indicating that ischemia-reperfusion significantly damaged the brain tissue, indicating that the model was successfully established. Rats treated with N3-LNE had minimal brain tissue damage, significantly lower than that in the LNE and NBP groups, indicating that the new N3-LNE formulation has good efficacy. The brain infarction rate in the LNE group was significantly lower than that in the MCAO group (p < 0.05), which may be related to the protective effect of nutrients such as phospholipids in LNE on brain damage.

[0175] ④TUNEL staining: The TUNEL staining results of the animals in each group are shown in Figure 12. The results showed that the nuclei of the brain tissue of the rats in the sham group were intact and there were no apoptotic cells. The rats in the MCAO group had large areas of green apoptotic cells in the right brain tissue, indicating that ischemia-reperfusion significantly damaged the brain tissue and the model was successfully established. The number of apoptotic cells in the brain tissue of the NBP, N3-LNE, and LNE groups was significantly lower than that of the MCAO group (p < 0.05), indicating that the drug administration in all three groups can effectively protect the brain tissue, which is consistent with the TTC staining results.

[0176] ⑤ Expression of inflammatory factors: The expression results of inflammatory factors TNF-α, IL-1β, and IL-6 in the brain tissue of each group of animals are shown in Figure 13. As can be seen from the figure, the expression of the three inflammatory factors in the brain tissue of rats in the MCAO group was significantly increased (p<0.05), indicating that cerebral ischemia-reperfusion produced significant inflammation and the model was successfully established; the three inflammatory factors in the N3-LNE group were significantly lower than those in the MCAO group (p<0.05), indicating that the new N3-LNE preparation effectively protected brain tissue and significantly reduced inflammation; compared with the MCAO group, the three inflammatory factors in the LNE group and the NBP group decreased, but there was no significant difference.

[0177] ⑥HE staining: The HE staining results of the muscles, heart, liver, spleen, kidney, and lung at the implantation sites of each group are shown in Figure 14. Compared with the sham group, no obvious pathological damage was observed in the heart, liver, spleen, lung, and kidney of the rats in the N3-LNE and LNE groups, indicating that they have good safety and further demonstrating that N3-LNE is a promising new preparation for the treatment of stroke.

[0178] From the above, we can see that the new preparation N3-LNE significantly reduced brain damage caused by cerebral ischemia-reperfusion in rats after treatment, accelerated the recovery of nervous system function; reduced the infarction rate and cell apoptosis of brain tissue, effectively protected brain tissue, and reduced inflammation caused by brain damage; it has good safety and is a promising new preparation for the treatment of stroke.

Claims

1. A 7-hydroxy-butylphthalide nanoemulsion preparation, characterized in that: The 7-hydroxy-butylphthalide nanoemulsion preparation comprises 7-hydroxy-butylphthalide, oil, phospholipid, phospholipid PEG derivative, surfactant and isotonic agent.

2. The 7-hydroxy-butylphthalide nanoemulsion according to claim 1, characterized in that: The oil is one or more of LCT, MCT and castor oil; the oil concentration is 5% to 30%.

3. The 7-hydroxy-butylphthalide nanoemulsion according to claim 1, characterized in that: The phospholipid is egg yolk lecithin or hydrogenated distearoyl phosphatidylcholine.

4. The 7-hydroxy-butylphthalide nanoemulsion according to claim 1, characterized in that: The surfactant is poloxamer and oleic acid; the isotonic agent is glycerol.

5. The 7-hydroxy-butylphthalide nanoemulsion preparation according to claim 1, characterized in that: The concentration of the phospholipid PEG derivative is 0.025-0.25%.

6. A method for preparing a 7-hydroxy-butylphthalide nanoemulsion, characterized in that: The steps include: a. Dissolving phospholipids and 7-hydroxy-butylphthalide in ethanol respectively, and then removing the ethanol by ultrasonic mixing or rotary evaporation to obtain an oily liquid, and then adding fat, oleic acid, and phospholipid PEG derivatives to the oily liquid to obtain an oil phase; b. Add surfactant and isotonic agent to water for injection in sequence, dissolve by ultrasonic until clear, and obtain aqueous phase; c. Add the water phase to the oil phase under stirring with a high-speed shearing machine, and shear at high speed until the solution becomes uniform milky white to obtain colostrum; d. The colostrum is transferred to a high-pressure homogenizer, and after homogenization, the volume is fixed with water for injection to obtain a 7-hydroxy-butylphthalide nanoemulsion preparation.

7. The method for preparing the 7-hydroxy-butylphthalide nanoemulsion according to claim 6, characterized in that: In step a, the oils are soybean oil and medium-chain triglycerides, and the mass ratio of the two is 1:1 to 1:4, and the total oil concentration is 5% to 30%.

8. The method for preparing the 7-hydroxy-butylphthalide nanoemulsion according to claim 6, characterized in that: In step a, the mass ratio of the phospholipid PEG derivative to the phospholipid is 1:100 to 20:100; the ratio of 7-hydroxy-butylphthalide to the total mass of the oil is 1:100 to 5:

100.

9. The method for preparing the 7-hydroxy-butylphthalide nanoemulsion according to claim 6, characterized in that: The concentration of 7-hydroxy-butylphthalide is 0.25 mg / mL to 5.0 mg / mL.

10. Use of the 7-hydroxy-butylphthalide nanoemulsion preparation according to claims 1-5 and the 7-hydroxy-butylphthalide nanoemulsion preparation prepared by the method according to claims 6-9 in the treatment of stroke.

Citation Information

Patent Citations

  • Composite type emulsifier, and emulsion prepared by using the emulsifier, and preparation method

    CN101091890A

  • Butylphthalide fat emulsion injection and preparation process thereof

    CN105796486A

  • Medical use of 7-hydroxy-butylphthalide

    CN106214674A

  • 7-hydroxy-butylphthalide nano-emulsion preparation as well as preparation method and application thereof

    CN116549388A

  • Emulsion medicine containing n-NBP for injection and its preparation method

    CN1839824A

Cited By

  • Biological nano-drug with blood platelets carrying bilobalide and butylphthalide as well as preparation method and application of biological nano-drug

    CN120549888A